Orion Biotechnology Canada Announces Appointment of New Director, Clinical Operations

Orion Biotechnology Canada Ltd. announced that Jarret Engstrom has joined as the company’s new Director, Clinical Operations. Mr. Engstrom will be responsible for design and implementation of the company’s early clinical development platform.

Ottawa, Canada (PRWEB) April 09, 2018 -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that Jarret Engstrom has joined as the company’s new Director, Clinical Operations. Mr. Engstrom will be responsible for design and implementation of the company’s early clinical development platform.

Jarret has a background in pre-clinical strategy and operations, CRO/CMO oversight, translational research and FDA regulated Investigational New Drug (IND) programs. His experience in clinical operations, management and the delivery of complex translational research protocols will be critical to helping rapidly bring our novel technologies to market.

Dr. Ian McGowan, Chief Scientific Officer at Orion Biotechnology, worked with Mr. Engstrom at the University of Pittsburg, and had this to say of the appointment; “Our efforts to improve health of the global population, through our pioneering work with novel treatments, will greatly benefit from Jarret’s skills and energy. We feel very fortunate to have attracted someone of Jarret’s talents to our company”. Commenting on his appointment, Mr. Engstrom, said, “I am thrilled to be joining Orion Biotechnology. The company’s growing pipeline of products offers real hope to a large population currently facing the risk of serious and, in some cases, chronic illnesses.”

Mr. Mark Groper, President and CEO of Orion Biotechnology added, “it takes different disciplines to successfully bring a new treatment from concept and initial formulation through to a proven market product. This includes; clinical trial design and management expertise. Our clinical team is elated to have Jarret lead this important function at Orion Biotechnology.”

About Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd, is a privately held pharmaceutical company founded on the vision of radically improving the health of the global population through successful treatment and prevention of the most serious chronic illnesses and life-threatening diseases. Since 2011, Orion has been developing a robust pipeline of potential products based on novel formulations discovered in different parts of the world. Our close ties to diverse institutions and experts around the globe continue to stimulate the rapid discovery of promising new treatments. With operations in North America, Europe and Asia, Orion brings together innovative technologies from some of the world’s leading research institutions, such as the Mintaka Research Foundation and the Center for Public Health Research at Nanjing University. Learn more at http://www.orionbiotechnology.com.

Forward-Looking Statements
This press release contains forward-looking information, which reflects Orion’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orion’s control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by
applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact Information
Ross MacLeod
Orion Biotechnology
http://orionbiotechnology.com
+1 343.291.1032

Online Web 2.0 Version
You can read the online version of this press release here.